Comparative Pharmacology
Head-to-head clinical analysis: MECLIZINE HYDROCHLORIDE versus TRINALIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MECLIZINE HYDROCHLORIDE versus TRINALIN.
MECLIZINE HYDROCHLORIDE vs TRINALIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meclizine is a histamine H1 receptor antagonist that acts centrally in the vestibular system to suppress nausea and vomiting. It also has anticholinergic and sedative effects.
TRINALIN is a combination of azatadine, a first-generation antihistamine that antagonizes histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors, causing vasoconstriction and reducing nasal congestion.
25-50 mg orally, 3 to 4 times daily for vertigo; 25-50 mg orally 1 hour before travel, may repeat every 24 hours as needed for motion sickness.
One tablet (azatadine 1 mg/pseudoephedrine 120 mg) orally every 12 hours. Not to exceed 2 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life: 6 hours (range 5-10 hours). Clinical context: Supports twice-daily dosing; steady-state achieved in approximately 24 hours.
Terminal elimination half-life approximately 20-30 hours; clinical context: allows twice-daily dosing for sustained decongestant effect
Renal (unchanged and metabolites): 50%; fecal: 40%; biliary: 10%
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30%
Category A/B
Category C
Antihistamine
Antihistamine/Decongestant